Fresh trial launched for COVID-19 drug in Japan: Fujifilm Holdings stated on Wednesday it started a new stage III test in Japan of its Avigan medication for COVID-19, reviving expect a home-grown treatment for the virus.
Residential authorization for the antiviral medicine to treat the coronavirus was dealt an obstacle in December after a health and wellness ministry panel said that test data was undetermined.
Fujifilm has over the years pivoted from its traditional cam and workplace services organizations to healthcare.
The new double-blind, placebo-controlled research is targeting patients aged 50 and older, in addition to those at risk of establishing significant problems, Fujifilm said in a launch.
Avigan, recognized generically as favipiravir, has been examined in loads of tests worldwide, and it has been accepted as a COVID-19 therapy in Russia, India and Indonesia. However concerns stay, as the medicine has been revealed to trigger abnormality in pet studies.
Japan has already approved Avigan as an emergency situation influenza medicine, and the federal government in 2015 called on Fujifilm to triple nationwide stockpiles of the medicine.